Loading clinical trials...
Loading clinical trials...
Phase 2 Study of LY2157299 in Patients With Hepatocellular Carcinoma
Conditions
Interventions
LY2157299
Sorafenib
+1 more
Locations
40
United States
Highlands Oncology Group
Fayetteville, Arkansas, United States
University of California, San Francisco
San Francisco, California, United States
Georgetown University Medical Center
Washington D.C., District of Columbia, United States
MD Anderson Cancer Center Orlando
Orlando, Florida, United States
Northwestern University
Chicago, Illinois, United States
Indiana Univ Melvin & Bren Simon Cancer Center
Indianapolis, Indiana, United States
Start Date
March 30, 2011
Primary Completion Date
June 6, 2019
Completion Date
December 24, 2019
Last Updated
January 12, 2021
NCT06571396
NCT06454578
NCT05870969
NCT02221778
NCT05389527
NCT04246177
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions